External preparation

Combining tranexamic acid with specific amino acids like arginine and glutamic acid inhibits crystallization, addressing the precipitation issue and ensuring effective use and appearance of external preparations.

JP2024163277APending Publication Date: 2024-11-21MARUZEN PHARMA
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2024157378
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2019-01-29
Filing Date
2024-09-11
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Tranexamic acid, despite its hemostatic and anti-inflammatory properties, is prone to crystallization due to its high water solubility, leading to precipitation issues, and existing methods like using phytic acid or polyhydroxy acid are not sufficiently effective in inhibiting this crystallization.

Method used

The combination of tranexamic acid with specific amino acids such as arginine, aspartic acid, glutamic acid, glycine, proline, serine, threonine, γ-aminobutyric acid, and their derivatives or salts effectively inhibits crystallization, with a synergistic effect observed in certain combinations.

Benefits of technology

The external preparation effectively suppresses tranexamic acid crystallization, maintaining its efficacy and providing a good appearance and user experience, with specific amino acid combinations showing enhanced inhibitory effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024163277000007
    Figure 2024163277000007
  • Figure 2024163277000001
    Figure 2024163277000001
  • Figure 2024163277000002
    Figure 2024163277000002
Patent Text Reader

Abstract

To provide an external preparation capable of suppressing crystallization of tranexamic acid.SOLUTION: An external preparation contains (A) one or more selected from tranexamic acid, tranexamic acid derivatives and salts of tranexamic acid or tranexamic acid derivatives, and (B) one or more selected from arginine, aspartic acid, glutamic acid, glycine, proline, serine, threonine, γ-aminobutyric acid, derivatives of these substances, and salts of these substances or the derivatives of these substances.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] The present invention relates to an external preparation containing tranexamic acid. [Background technology]

[0002] Tranexamic acid has hemostatic and anti-inflammatory effects and is widely used in dentifrices, pharmaceuticals, etc. It also has skin-relieving and whitening effects and is used as an external agent for the skin or hair, such as cosmetics.

[0003] However, while tranexamic acid is water-soluble, it has a problem of being highly crystalline and easily precipitates as crystals due to evaporation of water. As a method for inhibiting the crystallization of tranexamic acid, a method of using phytic acid (Patent Document 1: JP 2018-48097 A) or polyhydroxy acid (Patent Document 2: JP 2013-121955 A) in combination has been proposed. However, a method with an even better effect of inhibiting the crystallization of tranexamic acid is desired. [Prior art documents] [Patent documents]

[0004] [Patent Document 1] Japanese Patent Application Laid-Open No. 2018-48097 [Patent Document 2] Japanese Patent Application Laid-Open No. 2013-121955 Summary of the Invention [Problem to be solved by the invention]

[0005] The present invention has been made in view of the above circumstances, and an object of the present invention is to provide an external preparation having an effect of inhibiting the crystallization of tranexamic acid. [Means for solving the problem]

[0006] As a result of intensive research conducted by the present inventors to achieve the above object, they discovered that the combined use of a specific amino acid can achieve a significant effect of inhibiting the crystallization of tranexamic acid, and thus completed the present invention.

[0007] Therefore, the present invention provides the following topical preparations: Hereinafter, cosmetic label names may be used as ingredient names. 1. (A) one or more selected from tranexamic acid, tranexamic acid derivatives, and salts thereof, and (B) one or more selected from arginine, aspartic acid, glutamic acid, glycine, proline, serine, threonine, γ-aminobutyric acid, derivatives thereof, and salts of these and their derivatives An external preparation containing 2. The topical preparation according to 1, wherein component (B) is one or more selected from arginine, aspartic acid, glutamic acid, glycine, proline, serine, threonine, γ-aminobutyric acid, theanine, pyrrolidonecarboxylic acid, and salts thereof. [Effects of the Invention]

[0008] According to the present invention, it is possible to provide an external preparation having a remarkable effect of inhibiting the crystallization of tranexamic acid, thereby enabling the effects of tranexamic acid to be fully exerted and providing an external preparation with a good appearance and a good feel when used. [Brief explanation of the drawings]

[0009] [Figure 1] 10 shows photographs of samples after storage at room temperature for 24 hours in a crystallization inhibition test using 0.5 mass %, 0.25 mass %, and 0.125 mass % Asp, 0.16 mass % phytic acid, and blank tranexamic acid. DETAILED DESCRIPTION OF THE INVENTION

[0010] The present invention will be described in detail below. [Component (A)] Component (A) is at least one selected from tranexamic acid, tranexamic acid derivatives, and salts thereof, and can be used alone or in combination of two or more. Tranexamic acid is trans-4-aminomethylcyclohexane-1-carboxylic acid. Examples of tranexamic acid derivatives include ester derivatives such as tranexamic acid cetyl ester, and amide derivatives such as tranexamic acid methylamide. Examples of salts include, but are not limited to, alkali metal salts such as sodium and potassium, alkaline earth metal salts such as calcium and magnesium, metal salts such as aluminum, iron, and zinc, and organic amine salts such as ammonium, monoethanolamine, diethanolamine, triethanolamine, and stearylamine.

[0011] The content of component (A) is not particularly limited, but is preferably 1 to 5% by mass, more preferably 1 to 2% by mass in the topical preparation.

[0012] [(B) Component] The component (B) is one or more selected from arginine, aspartic acid, glutamic acid, glycine, proline, serine, threonine, γ-aminobutyric acid, derivatives thereof, and salts of these and their derivatives, and can be used alone or in appropriate combination of two or more.

[0013] The above-mentioned arginine, aspartic acid, glutamic acid, glycine, proline, serine, threonine, and γ-aminobutyric acid (GABA) are amino acids, and may be in the D-, L-, or DL-form. Examples of derivatives of these include ester derivatives in which the hydrogen atoms in the amino acids are substituted with alkyl, alkenyl, aryl, or other groups; ester derivatives in which the hydrogen atoms of the hydroxyl groups are substituted with acyl groups; ether derivatives in which the hydrogen atoms of the hydroxyl groups are substituted with alkyl, alkenyl, aryl, or other groups; amide derivatives in which the hydrogen atoms of the amino groups are substituted with acyl groups; and amine derivatives in which the hydrogen atoms of the amino groups are substituted with alkyl, alkenyl, aryl, or other groups. Specific examples include theanine and pyrrolidonecarboxylic acid, which are derivatives of glutamic acid.

[0014] The above-mentioned amino acid salts and salts of amino acid derivatives are not particularly limited, and examples thereof include alkali metal salts such as sodium and potassium, alkaline earth metal salts such as calcium and magnesium, metal salts such as aluminum, iron and zinc, and organic amine salts such as ammonium, monoethanolamine, diethanolamine, triethanolamine and stearylamine.

[0015] As component (B), arginine, aspartic acid, glutamic acid, glycine, proline, serine, threonine, γ-aminobutyric acid, theanine, pyrrolidonecarboxylic acid, and salts thereof are preferred in terms of the effect of inhibiting the crystallization of tranexamic acid.

[0016] The combination of glutamic acid or a salt thereof with γ-aminobutyric acid or a salt thereof, and the combination of γ-aminobutyric acid or a salt thereof with theanine are preferred because they can achieve a synergistic effect in the crystallization inhibitory effect of tranexamic acid.

[0017] The content of component (B) is not particularly limited, but is preferably 0.05 to 5% by mass, more preferably 0.125 to 2% by mass, and even more preferably 0.25 to 1% by mass in the topical preparation. By keeping it within this range, the crystallization-inhibiting effect of tranexamic acid is further improved.

[0018] In particular, in the case of the following components or salts thereof, the following ranges are particularly preferred. Arginine or a salt thereof: 0.5 to 2% by mass Aspartic acid: 0.125 to 1% by mass Glutamic acid: 0.125 to 1% by mass Glycine: 0.75 to 1.25% by mass Proline: 1 to 2% by mass Serine: 0.25 to 1% by mass Threonine: 0.5 to 1% by mass Theanine: 0.125 to 0.25% by mass γ-aminobutyric acid: 0.125 to 0.25% by mass Pyrrolidone carboxylic acid: 0.25 to 0.5% by mass

[0019] The mass ratio of the content of component (A) to component (B), represented by (A):(B), is preferably 20:1 to 0.5:1, more preferably 16:1 to 1:1, and even more preferably 8:1 to 2:1. By setting it within this range, the crystallization inhibitory effect of tranexamic acid is further improved.

[0020] [Optional ingredients] The topical preparation of the present invention can contain appropriate amounts of ingredients commonly used in topical preparations, provided that the effects of the present invention are not impaired. Examples of such ingredients include functional ingredients such as whitening agents, anti-aging agents, moisturizing agents, preservatives, antibacterial agents, enzymes, and plant extracts, as well as oils, surfactants, fragrances, colorants, pH adjusters, and purified water. These ingredients can be used alone or in appropriate combinations of two or more in appropriate amounts.

[0021] In particular, it is preferable to incorporate a polyhydric alcohol into the topical preparation of the present invention. The polyhydric alcohol may be used alone or in combination of two or more. Examples of polyhydric alcohols include isopentyl diol, ethyl hexanediol, caprylyl glycol, glycol, (C15-18) glycol, (C20-30) glycol, glycerin, diethylene glycol, diglycerin, dithiaoctanediol, dipropylene glycol, thioglycerin, 1,10-decanediol, decylene glycol, triethylene glycol, trimethylhydroxymethylcyclohexanol, phytantriol, phenoxypropanediol, 1,2-butanediol, 2,3-butanediol, butylethylpropanediol, 1,3-butylene glycol, butylene glycol, PG, 1,2-hexanediol, hexylene glycol, pentylene glycol, methylpropanediol, menthanediol, and lauryl glycol.

[0022] When a polyhydric alcohol is added, its content in the topical preparation is preferably 1.0 to 30.0% by mass, more preferably 2.0 to 30.0% by mass.

[0023] The topical preparations include, but are not limited to, pharmaceuticals, quasi-drugs, cosmetics, etc. Among these, topical preparations for skin and hair are suitable. The skin includes, but is not limited to, the face, scalp, arms, and other body parts, but does not include the oral cavity. The form of the topical preparation is not particularly limited, and may be a solution, suspension, emulsion, cream, ointment, gel, lotion, aerosol, etc. Examples of forms that are expected to have the effect of inhibiting the crystallization of tranexamic acid include solutions and lotions.

[0024] Examples of uses for external preparations, particularly external preparations for quasi-drugs or cosmetics, include basic cosmetics such as lotions, milky lotions, creams, gels, beauty serums, sunscreen cosmetics, packs, masks, hand creams, body lotions, and body creams; skin cleansers such as facial cleansers, makeup removers, and body shampoos; scalp and hair cosmetics such as shampoos, rinses, and treatments; and makeup cosmetics such as foundations, lipsticks, and mascaras.

[0025] The pH of the topical preparation is not particularly limited, but is preferably 3 to 8 at 25°C, more preferably 5.0 to 7.0.

[0026] [Method for inhibiting crystallization of tranexamic acid] The present invention provides a method for inhibiting the crystallization of tranexamic acid, which comprises blending (A) an external preparation containing one or more selected from tranexamic acid, tranexamic acid derivatives, and salts thereof with (B) one or more selected from arginine, aspartic acid, glutamic acid, glycine, proline, serine, threonine, γ-aminobutyric acid, derivatives thereof, and salts of these and their derivatives. The present invention also provides a crystallization inhibitor for tranexamic acid containing component (A) and component (B). The preferred components, amounts, etc., for each component are the same as those described above. [Example]

[0027] The present invention will be specifically described below with reference to examples and comparative examples, but the present invention is not limited to the following examples. In the following examples, unless otherwise specified, "%" in the composition indicates % by mass, ratio indicates mass ratio, and the amount of each component in the table is the amount converted into a pure content.

[0028] The following components were tested for their ability to inhibit crystallization of tranexamic acid at the concentrations shown in the table. The results are also shown in the table. [Test example: Inhibition of crystallization of tranexamic acid] (1) Test sample (pH 3-8) A composition having the following composition was prepared. Tranexamic acid 2% 1,3-butylene glycol 30% Sample Concentration shown in the table Purified water remainder Total 100%

[0029] (2) Test method The above composition was added to the following plate at 3.0 g / well, and after storing at room temperature for 24 hours, image analysis was carried out by the method described in (3) below. plate Manufactured by Stem Co., Ltd. Material: PS (polystyrene) Plate size: 128 x 86 x 20 mm Model number: 6 holes (flat bottom) Well diameter x height (mm): φ33.5 x 16.7

[0030] (3) Image analysis Image analysis Scanner: Docu Center-IV C5575 (Fuji Xerox) Image capture resolution: 300 dpi Image analysis software: ImageJ (ver. 1.50i) A circular area inside the well on the image was selected using the Oval tool, and the Mean gray value was measured using Analyze / Measure.

[0031] (4) Based on the results of the mean gray value, the crystallization inhibitory effect of tranexamic acid is shown according to the following criteria. The lower the value, the higher the crystallization inhibitory effect of tranexamic acid. +++: Less than 20 ++:20 or more and less than 40 +: 40 or more and less than 60 -:60 or more

[0032] Abbreviations are shown below. Ala: L-alanine Arg: L-arginine Asp: L-aspartic acid Cys: DL-cysteine Glu: L-glutamic acid Gly: L-glycine His: L-histidine Ile: L-isoleucine Pro: L-proline Ser: L-serine Thr: DL-Threonine Tyr: L-tyrosine Poly-Lys: Poly-L-lysine Poly-PA: Sodium polyphosphate Theanine: L-theanine GABA: gamma-aminobutyric acid PCA: DL-pyrrolidone carboxylic acid

[0033] [Table 1]

[0034] Figure 1 shows photographs of the above-mentioned tranexamic acid crystallization inhibition test samples (0.5%, 0.25%, 0.125% Asp, 0.16% phytic acid, and blank) stored at room temperature for 24 hours. It was confirmed that aspartic acid has a stronger effect of inhibiting tranexamic acid crystallization than phytic acid.

[0035] [Table 2]

[0036] From the above results, it was confirmed that arginine, aspartic acid, glutamic acid, glycine, proline, serine, threonine, theanine, γ-aminobutyric acid, and pyrrolidonecarboxylic acid have the effect of inhibiting the crystallization of tranexamic acid.

[0037] [Table 3]

[0038] From the above results, it was confirmed that alanine, cysteine, histidine, isoleucine, tyrosine, polylysine, and sodium polyphosphate had no inhibitory effect on the crystallization of tranexamic acid.

[0039] [Table 4]

[0040] [Table 5]

[0041] The results in Table 3 confirmed that the combined use of Glu: L-glutamic acid and GABA: γ-aminobutyric acid had a synergistic effect in inhibiting the crystallization of tranexamic acid. As can be seen from the results in Table 4, the total amount was adjusted to 0.125%, so if GABA and Theanine had an additive effect, it would be marked "+", but since it is marked "++", it was confirmed that the combined use of GABA: γ-aminobutyric acid and Theanine: L-theanine has a synergistic effect in inhibiting tranexamic acid crystallization.

[0042] [Examples and Comparative Examples] The ingredients other than purified water were mixed and dissolved in purified water to prepare a lotion with the composition shown in Table 4. The cosmetic product name is listed. The crystallization inhibitory effect of tranexamic acid was evaluated using the same method as above. The results are also shown in the table.

[0043]

Table 6

Claims

1. (A) one or more selected from tranexamic acid, tranexamic acid derivatives, and salts thereof, and (B) one or more selected from arginine, aspartic acid, glutamic acid, glycine, proline, serine, threonine, γ-aminobutyric acid, derivatives thereof, and salts of these and their derivatives. An external preparation containing.

2. 2. The topical preparation according to claim 1, wherein component (B) is at least one member selected from the group consisting of arginine, aspartic acid, glutamic acid, glycine, proline, serine, threonine, γ-aminobutyric acid, theanine, pyrrolidone carboxylic acid, and salts thereof.

Citation Information

Patent Citations

  • Composition for external and internal use containing tranexamic acid

    JP2013121955A

  • Cosmetic or skin external preparation containing tranexamic acid

    JP2018048097A